Kiyoharu Fukushima
Overview
Explore the profile of Kiyoharu Fukushima including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
62
Citations
570
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hara R, Takeda Y, Enomoto T, Yoshimura H, Yamamoto M, Tanizaki S, et al.
J Allergy Clin Immunol Glob
. 2025 Mar;
4(2):100432.
PMID: 40046156
Background: Bronchial asthma (BA) and chronic obstructive pulmonary disease (COPD) are often misdiagnosed or undiagnosed, highlighting the need for more noninvasive and accessible diagnostic tools. Although exhaled breath condensate (EBC)...
2.
Hashimoto K, Abe Y, Fukushima K, Matsumoto Y, Saito H, Akamine Y, et al.
Emerg Infect Dis
. 2025 Mar;
31(3):624-627.
PMID: 40023820
We identified 2 novel species, Mycobacterium novusgordonae and M. shingordonae, from sputum specimens of pulmonary disease patients in Japan. Genetic and biochemical analyses revealed a close relationship with M. paragordonae....
3.
Hashimoto K, Abe Y, Fukushima K, Niitsu T, Komukai S, Miyamoto S, et al.
BMC Pulm Med
. 2024 Oct;
24(1):531.
PMID: 39448945
Background: The characteristics of bronchiectasis (BE) in Asia, including Japan, remain largely unknown. We aimed to provide insights into the clinical characteristics and treatment outcomes of BE, especially regarding nontuberculous...
4.
Fukushima K, Matsumoto Y, Abe Y, Hashimoto K, Motooka D, Kitada S, et al.
Antimicrob Agents Chemother
. 2024 Oct;
68(11):e0121324.
PMID: 39377582
This single-center retrospective study aimed to analyze the variability of macrolide resistance (MR) in 68 patients with complex pulmonary disease. Among 25 patients treated without macrolides, 13 (52%) reverted to...
5.
Enomoto T, Shirai Y, Takeda Y, Edahiro R, Shichino S, Nakayama M, et al.
JCI Insight
. 2024 Jun;
9(11).
PMID: 38855869
Progressive pulmonary fibrosis (PPF), defined as the worsening of various interstitial lung diseases (ILDs), currently lacks useful biomarkers. To identify novel biomarkers for early detection of patients at risk of...
6.
Sun X, Nagahama Y, Singh S, Kozakai Y, Nabeshima H, Fukushima K, et al.
Immunity
. 2024 May;
57(6):1360-1377.e13.
PMID: 38821052
Limited infiltration and activity of natural killer (NK) and T cells within the tumor microenvironment (TME) correlate with poor immunotherapy responses. Here, we examined the role of the endonuclease Regnase-1...
7.
Yoshimura H, Takeda Y, Shirai Y, Yamamoto M, Nakatsubo D, Amiya S, et al.
J Allergy Clin Immunol
. 2024 Mar;
153(5):1268-1281.
PMID: 38551536
Background: Novel biomarkers (BMs) are urgently needed for bronchial asthma (BA) with various phenotypes and endotypes. Objective: We sought to identify novel BMs reflecting tissue pathology from serum extracellular vesicles...
8.
Tone M, Iwahori K, Shiroyama T, Futami S, Naito Y, Fukushima K, et al.
Sci Rep
. 2023 May;
13(1):8313.
PMID: 37221285
Minocycline is often administered prophylactically or therapeutically to non-small cell lung cancer (NSCLC) patients receiving epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) for skin rash as an adverse event. We...
9.
Naito Y, Koyama S, Masuhiro K, Hirai T, Uenami T, Inoue T, et al.
Sci Adv
. 2023 May;
9(20):eade0718.
PMID: 37205755
Immune checkpoint inhibitors (ICIs) have caused revolutionary changes in cancer treatment, but low response rates remain a challenge. Semaphorin 4A (Sema4A) modulates the immune system through multiple mechanisms in mice,...
10.
Nabeshima H, Niitsu T, Fukushima K, Kida H
Cell Mol Immunol
. 2023 May;
20(10):1095-1097.
PMID: 37147375
No abstract available.